FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Richard John P
2. Issuer Name and Ticker or Trading Symbol

Vaxart, Inc. [ VXRT ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

C/O VAXART, INC., 290 UTAH AVE. SUITE 200
3. Date of Earliest Transaction (MM/DD/YYYY)

10/11/2019
(Street)

SOUTH SAN FRANCISCO, CA 94080
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common stock  10/11/2019    P    20000  A $0.384  20000  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Richard John P
C/O VAXART, INC.
290 UTAH AVE. SUITE 200
SOUTH SAN FRANCISCO, CA 94080
X



Signatures
/s/ John P. Richard 10/15/2019
**Signature of Reporting Person Date


Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Vaxart Charts.
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Vaxart Charts.

Vaxart, Inc. News

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers
Tuesday 30 April 2024 (1 day ago) • GlobeNewswire Inc.
Vaxart to Present at World Vaccine Congress Washington 2024 on April 3
Wednesday 27 March 2024 (1 month ago) • GlobeNewswire Inc.
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Wednesday 20 March 2024 (1 month ago) • GlobeNewswire Inc.
Vaxart Provides Business Update and Reports Full Year 2023 Financial Results
Thursday 14 March 2024 (2 months ago) • GlobeNewswire Inc.
U.S. Stock Futures Rise Ahead Of PPI and Retail Sales; Oil Prices Climb
Thursday 14 March 2024 (2 months ago) • IH Market News
Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14
Thursday 7 March 2024 (2 months ago) • GlobeNewswire Inc.
Form 8-K - Current report
Wednesday 6 March 2024 (2 months ago) • Edgar (US Regulatory)
Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director
Wednesday 6 March 2024 (2 months ago) • GlobeNewswire Inc.
Form 8-K - Current report
Thursday 29 February 2024 (2 months ago) • Edgar (US Regulatory)
Form 8-K - Current report
Thursday 15 February 2024 (2 months ago) • Edgar (US Regulatory)
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Tuesday 13 February 2024 (3 months ago) • Edgar (US Regulatory)
Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge
Monday 5 February 2024 (3 months ago) • GlobeNewswire Inc.